bezafibrate/diflunisal (CRx-401) / Sun Pharma - LARVOL DELTA

SINGLE-MICROGLIA TRANSCRIPTOMIC TRANSITION NETWORK-BASED PREDICTION AND REAL-WORLD PATIENT DATA VALIDATION IDENTIFIES KETOROLAC AS A REPURPOSABLE DRUG FOR ALZHEIMER'S DISEASE (ADPD 2025) - "We presented a network-based drug repurposing prediction by specifically blocking transition networks from neuroinflammation like microglia (NIM) to non-NIM and we identified a set of highly repurposable drugs (i.e., ketorolac, diflunisal, bezafibrate, and isradipine) for potential treatment of AD. Using two independent real-world patient databases (MarketScan [172 million insured individuals] and INSIGHT Clinical Research Network [15 million patients]), we identified that usage of Ketorolac was associated with reduced AD incidence in both MarketScan (hazard ratio [HR] = 0.89) and INSIGHT (HR = 0.83) Clinical Research Network databases, mechanistically supported by Ketorolac-treated transcriptomic data from AD patient iPSC-derived microglia. Conclusions This study offers insights into the pathobiology of AD-relevant microglial subtypes and identifies Ketorolac as a potential anti-inflammatory treatment for AD."

Clinical • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Inflammation • ADAM10 • INPP5D • PRKCA • SYK

Tafamidis May Be More Effective Than Diflunisal in Slowing ATTR-CM Progression - "The team led by Frederick Ruberg, MD...analyzed 164 patients with ATTR-CM seen at the university's Amyloidosis Center from 2016 to 2022."